PANews reported on November 21 that according to Globenewswire, Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a US listed company, announced yesterday that the company's board of directors approved the purchase of up to $1 million in Bitcoin as part of its cash management strategy. Enlivex CEO Oren Hershkovitz said: "With the growing demand for Bitcoin and its increasing acceptance as a recognized medium of exchange, we believe that Bitcoin will become a strong and diversified reserve asset for the company. With the recent approval of the Bitcoin ETF and the increasing support from institutional investors, we believe that Bitcoin can provide the company with potential functional value storage and inflation hedge for standard currencies."

According to reports, Enlivex is a clinical-stage macrophage reprogramming immunotherapy company.